Unraveling Metabolic Dysfunction-Associated Fatty Liver Disease: Refining Sub-Phenotypes for Resolving Its Heterogeneity

참고문헌 (10)

1. Loomba R, "The global NAFLD epidemic", Nat Rev Gastroenterol Hepatol, 10, pp.686~690 (2013)
2. Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 149, pp.389~397 (2015)
3. Eslam M, "A new definition for metabolic dysfunction-associated fatty liver disease : an international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
4. Younossi ZM, "Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?", Hepatology, 76, pp.1423~1437 (2022)
5. Lim Tae Seop, "Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes", Gut and Liver, 17(4), pp.610~619 (2023), 거트앤리버 소화기연관학회협의회[DOI]
6. Cheng Han Ng, "Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name", Clinical and Molecular Hepatology, 28(4), pp.790~801 (2022), 대한간학회
7. Chen X, "Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality?", J Hepatol, 75, pp.987~989 (2021)
8. Kang MK, "Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease", Hepatol Int, 17, pp.626~635 (2023)
9. Lee H, "Metabolic dysfunctionassociated fatty liver disease and incident cardiovascular disease risk : a nationwide cohort study", Clin Gastroenterol Hepatol, 19, pp.2138~2147 (2021)
10. Tsutsumi T, "MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD : Generalized estimating equation approach", Hepatol Res, 51, pp.1115~1128 (2021)

관련 논문AI추천